Transparent clinical operations have become a defining differentiator for high-performing contract research organizations. Yet many medical device and wearable developers still encounter opaque decision-making, limited protocol visibility, and communication gaps that slow execution and create unnecessary regulatory friction. The result is predictable: CRO risk mitigation becomes reactive instead of proactive , and promising technologies reach the FDA or CE mark later than the